Clinical Evaluation of Sizofilan as Assistant Immunotherapy in Treatment of Head and Neck Cancer
- 1 January 1994
- journal article
- clinical trial
- Published by Taylor & Francis in Acta Oto-Laryngologica
- Vol. 114 (sup511) , 192-195
- https://doi.org/10.3109/00016489409128330
Abstract
Sizofilan (SPG), a simple glucan produced in a culture medium by Schizophyllum commune Feries, was used as an assistant immunotherapy in 15 patients with head and neck cancer. The cumulative 5-year survival rate was 86.7% in the SPG-treated group and 73.4% in the control group. Immunological parameters showed that the SPG group quickly recovered the cellular immunity damaged by radiation, chemotherapy and surgical procedure. SPG was found to be effective as an assistant immunotherapeutic agent in the treatment of head and neckKeywords
This publication has 4 references indexed in Scilit:
- Clinical evaluation of adjuvant immunotherapy with Sizofiran(SPG) for postoperative head and neck cancer.Japanese Journal of Oral and Maxillofacial Surgery, 1991
- Clinical evaluation of sizofiran combined with irradiation in patients with cervical cancerBiotherapy, 1989
- Clinical evaluation of schizophyllan combined with irradiation in patients with cervical cancer: A randomized controlled studyCancer, 1986
- Clinical evaluation of schizophyllan adjuvant immunochemotherapy for patients with resectable gastric cancer —A randomized controlled trial—Surgery Today, 1984